Items where Subject is "Australian and New Zealand Standard Research Classification > MEDICAL AND HEALTH SCIENCES (110000) > ONCOLOGY AND CARCINOGENESIS (111200) > Chemotherapy (111205)"
|Up a level|
- Subjects classification (47368)
- Australian and New Zealand Standard Research Classification (47368)
Group by: Authors/Creators | Item Type
Number of items at this level: 16.
Abbott, J., Teleni, L., McKavanagh, D., Watson, J., McCarthy, A.L., & Isenring, E. (2016) Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF) is a valid screening tool in chemotherapy outpatients. Supportive Care in Cancer. (In Press)
Byron, Sara A., Loch, David, & Pollock, Pamela M. (2012) Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. International Journal of Gynecological Cancer, 22(9), pp. 1517-1526.
Chan, Raymond (2010) Cochrane review summary for cancer nursing : influenza vaccination in children having chemotherapy for cancer. Cancer Nursing An International Journal for Cancer Care, 33(4), pp. 327-328.
Chan, Raymond (2012) The two cs to evidence-based infusion nursing : critical examination and collaboration. Journal of Infusion Nursing, 35(4), pp. 208-209.
Chan, Raymond Javan, Alexander, Alison , Bransdon, Maree , Webster, Joan , Hughes, Brett Gordon Maxwell, Brown, Leisa , et al. (2012) Challenging the distal-to-proximal cannulation technique for administration of anti-cancer therapies : a prospective cohort study. Cancer Nursing, 35(5), e35-40.
Dutton-Regester, Ken & Hayward, Nicholas K. (2012) Whole genome and exome sequencing of melanoma. Advances in Pharmacology, 65, pp. 399-435.
Dutton-Regester, Ken, Irwin, Darryl, Hunt, Priscilla, Aoude, Lauren G., Tembe, Varsha, Pupo, Gulietta M., et al. (2012) A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Molecular Cancer Therapeutics, 11(4), pp. 888-897.
Eyob, Tewodros, Ng, Terence, Chan, Raymond, & Chan, Alexandre (2016) Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: A systematic review of quantitative studies. Current Opinion in Supportive and Palliative Care, 10(2), pp. 165-179.
Jekimovs, Christian, Bolderson, Emma, Suraweera, Amila, Adams, Mark, O'Byrne, Kenneth J., & Richard, Derek J. (2014) Chemotherapeutic compounds targeting the DNA double-strand break repair pathways : the good, the bad, and the promising. Frontiers in Oncology, 4(86).
Libério, Michelle S., Sadowski, Martin, Davis, Rohan, Rockstroh, Anja, Vasireddy, Raja S., Lehman, Melanie L., et al. (2015) The ascidian natural product eusynstyelamide B is a novel topoisomerase II poison that induces DNA damage and growth arrest in prostate and breast cancer cells. Oncotarget, 6(41), pp. 43944-43963.
Packer, Leisl M., Rana, Sareena, Hayward, Robert, O'Hare, Thomas, Eide, Christopher A., Rebocho, Ana, et al. (2011) Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell, 20(6), pp. 715-727.
Sharkey, Annabel J., O’Byrne, Kenneth J., Nakas, Apostolos, Tenconi, Sara, Fennell, Dean A., & Waller, David A. (2016) How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? Lung Cancer, 100, pp. 5-13.
Singh, P, Yam, M, Russell, Pamela, & Khatri, Aparajita (2010) Molecular and traditional chemotherapy: A united front against prostate cancer. Cancer Letters, 293(1), pp. 1-14.
Skerman, Helen M., Yates, Patsy M., & Battistutta, Diana (2011) Cancer-related symptom clusters for symptom management in outpatients after commencing adjuvant chemotherapy, at 6 months, and 12 months. Supportive Care in Cancer, 20(1), pp. 95-105.
Tong, H. Tammy, Isenring, Elisabeth A., & Yates, Patsy (2008) The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. Supportive Care In Cancer, 17(1), pp. 83-90.
Yang, J.C.-H., Sequist, L.V., Zhou, C., Schuler, M., Geater, S.L., Mok, T., et al. (2016) Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hocanalyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology, 27(11), pp. 2103-2110.